A 52-Week, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Phase IIb Trial to Determine the Effects of Bardoxolone Methyl (RTA 402) on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease With an eGFR of 20 - 45 mL/Min/1.73m2.

Trial Profile

A 52-Week, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Phase IIb Trial to Determine the Effects of Bardoxolone Methyl (RTA 402) on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease With an eGFR of 20 - 45 mL/Min/1.73m2.

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Nov 2016

At a glance

  • Drugs Bardoxolone methyl (Primary)
  • Indications Diabetic nephropathies
  • Focus Therapeutic Use
  • Acronyms BEAM
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 14 Nov 2016 Results published in the Reata Pharmaceuticals Media Release
    • 24 Jun 2011 Primary endpoint 'Glomerular-filtration-rate' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top